Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stocks rise 65.9% post-IPO for newly public biotech companies

This article was originally published in Scrip

Executive Summary

Biotechnology investment bubble or not, the average return on investment for 29 drug developers that launched initial public offerings during the first nine months of the year is 65.9%. That's a compelling figure for companies trying to decide if they should go public in 2013 and for investors considering whether to participate in biotech IPOs.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC023008

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel